Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.

Publication Type:

Journal Article

Source:

Cancer, Volume 109, Issue 6, p.1011-8 (2007)

Keywords:

Antineoplastic Agents, Hormonal, Breast Neoplasms, Chemotherapy, Adjuvant, Cost-Benefit Analysis, Disease-Free Survival, Female, gene expression, Humans, Lymph Nodes, Monte Carlo Method, Neoplasm Recurrence, Local, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, RNA, Messenger, Tamoxifen, Treatment Outcome

Abstract:

The prognostic accuracy for distant recurrence-free survival using a 21-gene reverse-transcriptase polymerase chain reaction (RT-PCR) assay underwent validation in 668 lymph node-negative, estrogen receptor-positive women with early-stage breast cancer receiving tamoxifen on National Surgical Adjuvant Breast Program (NSABP) B-14. The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14.